Is white-coat hypertension associated with increased cardiovascular and mortality risk?

Journal of Hypertension

Volumn 34, Issue 8, 2016, Pages 1655-1658

  Muntner, Paul ^a   Booth, John N ^a   Shimbo, Daichi ^b   Schwartz, Joseph E ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Columbia University ^*  (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GROUPS BY AGE; HOME MONITORING; HUMAN; LETTER; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION; BLOOD PRESSURE MEASUREMENT; HYPERTENSION; RISK; RISK FACTOR;

BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; HYPERTENSION; RISK; RISK FACTORS; WHITE COAT HYPERTENSION;

EID: 84976885363     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000983     Document Type: Letter

References (27)

1. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH How Common Is White Coat Hypertension? JAMA 1988; 259:225-228
2. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354:2368-2374.
3. Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Role of ambulatory and home blood pressure monitoring in clinical practice: a narrative review. Ann Intern Med 2015; 163:691-700.
4. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011; 378:1219-1230.
5. National Institute for Health, Clinical Excellence. NICE clinical guideline 127. Hypertension: Clinical management of primary hypertension in adults. London: NICE 2011.
6. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-Analysis. J Hypertens 2016; 34:593-599.
7. Tanner RM, Shimbo D, Seals SR, Reynolds K, Bowling CB, Ogedegbe G, et al. White-coat effect among older adults: data from the Jackson Heart Study. J Clin Hypertens 2016; 18:139-145.
8. Zanchetti A, Mancia G Longing for Clinical Excellence: A Critical Outlook into the NICE Recommendations on Hypertension Management-is Nice Always Good? J Hypertens 2012; 30:660-668
9. Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-Analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012; 59:564-571.
10. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of masked hypertension detected by blood pressure self-measurement in elderly treated hypertensive patients. Jama 2004; 291:1342-1349.
11. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) trial investigators. Circulation 2000; 102:1139-1144.
12. Gustavsen PH, Hoegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens 2003; 17:811-817.
13. Hanninen MR, Niiranen TJ, Puukka PJ, Johansson J, Jula AM. Prognostic significance of masked and white-coat hypertension in the general population: the Finn-Home Study. J Hypertens 2012; 30:705-712.
14. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 2006; 19:243-250.
15. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Sleep-Time blood pressure and the prognostic value of isolated-office and masked hypertension. Am J Hypertens 2012; 25:297-305.
16. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998; 98:1892-1897.
17. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-Term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47:846-853.
18. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, et al. Long-Termprognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013; 62:168-174.
19. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46:508-515.
20. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short-And long-Term risk of cardiovascular events in white-coat hypertension. J Hum Hypertens 2008; 22:408-414.
21. Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 2014; 63:675-682.
22. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
23. Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015; 66:2159-2169.
24. Siu AL, Force USPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163:778-786.
25. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
26. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30:485-501.
27. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15.